Catalent Pharma Solutions: Business Overview, Financials & Competitive Analysis
Catalent Pharma Solutions scores 7/10 on the AskCyborg Cyborg Score (Strong). Essential infrastructure play in drug manufacturing with durable, long-term customer contracts and exposure to high-growth biologics and cell therapy markets. Market-leading CDMO with dominant FDA approval support, extensive global capacity, and scale ($4.42B TTM revenue). Strategic backing by Novo Holdings and expanding cell/gene therapy capabilities support growth. Transition to.
What is Catalent Pharma Solutions's industry? Catalent Pharma Solutions (catalent.com) operates in Pharmaceuticals. AskCyborg classifies Catalent Pharma Solutions under Pharmaceuticals in its company registry.
Catalent is a leading global Contract Development and Manufacturing Organization (CDMO), trusted by pharma, biotech and self-care companies to accelerate the development, manufacturing and delivery of products that im...
Cyborg Score thesis
Essential infrastructure play in drug manufacturing with durable, long-term customer contracts and exposure to high-growth...
Read the full analyst-debate transcript →Get the Latest Catalent Pharma Solutions Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCatalent Pharma Solutions Overview
Pro stress-test →Catalent is a leading global Contract Development and Manufacturing Organization (CDMO), trusted by pharma, biotech and self-care companies to accelerate the development, manufacturing and delivery of products that improve lives. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply.
Strategic Profile
Pro stress-test →With over 50 facilities on four continents, Catalent has supported more than half the products approved by the Food and Drug Administration in the last ten years and annually produces 70 billion doses for 8,000 products. The company derives its revenues primarily from long-term supply agreements with pharmaceutical customers.
Competitive Landscape
Pro stress-test →Catalent competes with major global CDMOs including Lonza, Samsung BioLogics, and Recipharm. The company maintains competitive advantages through scale, FDA approval track record, diverse technology platforms (oral solids, biologics, softgel, cell/gene therapy), and long-term customer relationships. Regional competitors and specialized boutique CDMOs serve niche segments.
Industry Context
Catalent Pharma Solutions operates in Pharmaceuticals.
Key facts
Founded: 2007 · Headquarters: Tampa, US · Employees: 12,602 · Revenue: $4.42B